Mydecine Innovations Group Inc. Stock NEO Exchange
Equities
MYCO
CA62849F2008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | +45.83% | +29.63% | -61.11% |
Feb. 23 | Mydecine Innovations Closes Partial Debt Settlement | MT |
Feb. 02 | Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director | CI |
Sales 2021 | 0.01 0.01 | Sales 2022 | - | Capitalization | 7.58M 10.38M |
---|---|---|---|---|---|
Net income 2021 | -28M -38.37M | Net income 2022 | -11M -15.07M | EV / Sales 2021 | 5,249,560,605 x |
Net Debt 2021 | 3.01M 4.12M | Net Debt 2022 | 153K 210K | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.13
x | P/E ratio 2022 |
-0.44
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.04% |
1 day | +45.83% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Roscow
FOU | Founder | - | 13-09-26 |
Damon Michaels
FOU | Founder | - | 13-09-26 |
David Bartch
CEO | Chief Executive Officer | - | 18-06-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bartch
CEO | Chief Executive Officer | - | 18-06-21 |
Damon Michaels
FOU | Founder | - | 13-09-26 |
Robert Roscow
FOU | Founder | - | 13-09-26 |
1st Jan change | Capi. | |
---|---|---|
-0.02% | 42.11B | |
+43.29% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- MYCOF Stock
- MYCO Stock